4 Citations (Scopus)

Abstract

Background: There are two main classes of Abs directed against the CD20 Ag that have been developed for therapeutic intent: Unconjugated and radiolabeled Abs. Methods: The clinical results available from the large clinical trials utilizing both the unconjugated and radiolabelled Abs are summarized in this article. Discussion: Both of these classes of agents have shown promise in clinical trials both alone and in conjunction with conventional chemotherapy or high-dose chemotherapy and transplantation. Ongoing research with these agents will provide further evidence of the place in clinical practice for these agents.

Original languageEnglish (US)
Pages (from-to)455-461
Number of pages7
JournalCytotherapy
Volume2
Issue number6
DOIs
StatePublished - Jan 1 2000

Fingerprint

Therapeutic Uses
Clinical Trials
Drug Therapy
Transplantation
Research
Therapeutics

Keywords

  • Bexxar
  • Monoclonal antibodies
  • Rituximab
  • Zevalin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Transplantation
  • Cancer Research

Cite this

Therapeutic uses of MAbs directed against CD20. / Vose, Julie Marie.

In: Cytotherapy, Vol. 2, No. 6, 01.01.2000, p. 455-461.

Research output: Contribution to journalArticle

@article{0ce488b8d7064efa892bc6213114e040,
title = "Therapeutic uses of MAbs directed against CD20",
abstract = "Background: There are two main classes of Abs directed against the CD20 Ag that have been developed for therapeutic intent: Unconjugated and radiolabeled Abs. Methods: The clinical results available from the large clinical trials utilizing both the unconjugated and radiolabelled Abs are summarized in this article. Discussion: Both of these classes of agents have shown promise in clinical trials both alone and in conjunction with conventional chemotherapy or high-dose chemotherapy and transplantation. Ongoing research with these agents will provide further evidence of the place in clinical practice for these agents.",
keywords = "Bexxar, Monoclonal antibodies, Rituximab, Zevalin",
author = "Vose, {Julie Marie}",
year = "2000",
month = "1",
day = "1",
doi = "10.1080/146532400539404",
language = "English (US)",
volume = "2",
pages = "455--461",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Therapeutic uses of MAbs directed against CD20

AU - Vose, Julie Marie

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: There are two main classes of Abs directed against the CD20 Ag that have been developed for therapeutic intent: Unconjugated and radiolabeled Abs. Methods: The clinical results available from the large clinical trials utilizing both the unconjugated and radiolabelled Abs are summarized in this article. Discussion: Both of these classes of agents have shown promise in clinical trials both alone and in conjunction with conventional chemotherapy or high-dose chemotherapy and transplantation. Ongoing research with these agents will provide further evidence of the place in clinical practice for these agents.

AB - Background: There are two main classes of Abs directed against the CD20 Ag that have been developed for therapeutic intent: Unconjugated and radiolabeled Abs. Methods: The clinical results available from the large clinical trials utilizing both the unconjugated and radiolabelled Abs are summarized in this article. Discussion: Both of these classes of agents have shown promise in clinical trials both alone and in conjunction with conventional chemotherapy or high-dose chemotherapy and transplantation. Ongoing research with these agents will provide further evidence of the place in clinical practice for these agents.

KW - Bexxar

KW - Monoclonal antibodies

KW - Rituximab

KW - Zevalin

UR - http://www.scopus.com/inward/record.url?scp=0034477864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034477864&partnerID=8YFLogxK

U2 - 10.1080/146532400539404

DO - 10.1080/146532400539404

M3 - Article

VL - 2

SP - 455

EP - 461

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 6

ER -